QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.57 (-0.05%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.32 (+5.01%)
AMD   98.26 (+2.24%)
T   15.09 (-1.44%)
F   12.58 (+3.11%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.74 (-0.22%)
DIS   82.09 (-0.77%)
AMC   7.96 (+3.38%)
PFE   32.75 (-0.30%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.57 (-0.05%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.32 (+5.01%)
AMD   98.26 (+2.24%)
T   15.09 (-1.44%)
F   12.58 (+3.11%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.74 (-0.22%)
DIS   82.09 (-0.77%)
AMC   7.96 (+3.38%)
PFE   32.75 (-0.30%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.57 (-0.05%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.32 (+5.01%)
AMD   98.26 (+2.24%)
T   15.09 (-1.44%)
F   12.58 (+3.11%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.74 (-0.22%)
DIS   82.09 (-0.77%)
AMC   7.96 (+3.38%)
PFE   32.75 (-0.30%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)
QQQ   361.67 (+1.06%)
AAPL   176.52 (+1.49%)
MSFT   320.59 (+0.33%)
META   303.14 (+2.51%)
GOOGL   131.75 (+1.00%)
AMZN   131.57 (+1.73%)
TSLA   255.57 (-0.05%)
NVDA   420.26 (+2.46%)
NIO   8.56 (+1.30%)
BABA   88.32 (+5.01%)
AMD   98.26 (+2.24%)
T   15.09 (-1.44%)
F   12.58 (+3.11%)
MU   69.44 (+2.27%)
CGC   0.85 (+10.58%)
GE   112.74 (-0.22%)
DIS   82.09 (-0.77%)
AMC   7.96 (+3.38%)
PFE   32.75 (-0.30%)
PYPL   58.88 (+0.44%)
NFLX   383.85 (-0.08%)

Nevro (NVRO) Stock Forecast, Price & News

$19.44
-0.07 (-0.36%)
(As of 11:51 AM ET)
Compare
Today's Range
$19.27
$19.70
50-Day Range
$18.20
$24.96
52-Week Range
$17.88
$50.54
Volume
124,136 shs
Average Volume
573,821 shs
Market Capitalization
$702.17 million
P/E Ratio
1,945.95
Dividend Yield
N/A
Price Target
$30.62

Nevro MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
58.1% Upside
$30.62 Price Target
Short Interest
Bearish
6.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Nevro in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.96) to ($2.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

521st out of 966 stocks

Surgical & Medical Instruments Industry

61st out of 92 stocks


NVRO stock logo

About Nevro (NYSE:NVRO) Stock

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Price History

NVRO Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here’s Why Nevro Corp. (NVRO) Declined in Q2
What 21 Analyst Ratings Have To Say About Nevro
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Expert Ratings for Nevro
Why Shares of Nevro Are Down Wednesday
Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut
JMP Securities Remains a Buy on Nevro Corp (NVRO)
RBC Capital Remains a Buy on Nevro Corp (NVRO)
What 17 Analyst Ratings Have To Say About Nevro
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Company Calendar

Last Earnings
8/01/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,087
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.62
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+56.8%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
14 Analysts

Profitability

Net Income
$3 million
Pretax Margin
1.00%

Debt

Sales & Book Value

Annual Sales
$406.36 million
Book Value
$9.14 per share

Miscellaneous

Free Float
35,036,000
Market Cap
$705.06 million
Optionable
Optionable
Beta
0.88
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. D. Keith GrossmanMr. D. Keith Grossman (Age 63)
    Exec. Chairman
    Comp: $1.75M
  • Mr. Roderick H. MacLeod (Age 56)
    Sr. VP & CFO
    Comp: $729.61k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 49)
    Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $703.35k
  • Mr. Kevin R. Thornal (Age 49)
    Pres, CEO & Director
  • Mr. Richard B. Carter (Age 52)
    Chief Accounting Officer
  • Mr. Christofer Christoforou (Age 53)
    Sr. VP of Technical Operations
  • Mr. Jon R. Shear
    Sr. VP of Corp. Devel.
  • Meredith Vornholt
    VP of Global Marketing
  • Dr. David Caraway M.D. (Age 66)
    Ph.D., Sr. VP & Chief Medical Officer
  • Mr. Donald A. Middlebrook (Age 72)
    Sr. VP of Clinical & Regulatory Affairs













NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price forecast for 2023?

14 brokerages have issued 1 year price objectives for Nevro's stock. Their NVRO share price forecasts range from $21.00 to $57.00. On average, they expect the company's share price to reach $30.62 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2023?

Nevro's stock was trading at $39.60 at the start of the year. Since then, NVRO stock has decreased by 50.7% and is now trading at $19.52.
View the best growth stocks for 2023 here
.

Are investors shorting Nevro?

Nevro saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,390,000 shares, an increase of 27.8% from the August 15th total of 1,870,000 shares. Based on an average daily volume of 539,400 shares, the days-to-cover ratio is currently 4.4 days.
View Nevro's Short Interest
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Tuesday, August, 1st. The medical equipment provider reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The medical equipment provider earned $108.80 million during the quarter, compared to analysts' expectations of $108.19 million. Nevro had a net margin of 0.61% and a negative trailing twelve-month return on equity of 32.73%. The firm's revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.71) earnings per share.

What ETFs hold Nevro's stock?
What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $109.25 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.37%), ArrowMark Colorado Holdings LLC (5.03%), State Street Corp (3.11%), Assenagon Asset Management S.A. (2.76%), Principal Financial Group Inc. (2.00%) and Geode Capital Management LLC (1.94%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $19.52.

How much money does Nevro make?

Nevro (NYSE:NVRO) has a market capitalization of $705.06 million and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or $0.01 on an earnings per share basis.

How many employees does Nevro have?

The company employs 1,087 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -